BioCryst Recieves $12M to Develop Ebola Drug

Durham-based BioCryst Pharmaceuticals is receiving $12 million from the federal government to fund further development of a possible drug to treat the deadly Ebola virus.

BioCryst Earns Special FDA designation

BioCryst Pharmaceuticals received Fast Track designation for its experimental treatment for hereditary angioedema.

BioCryst Hires Chief Commercial Officer

BioCryst has hired Lynne Powell as its Chief Commercial Officer.

FDA Approves BioCryst Flu Treatment

Durham's biotech company BioCryst has had its flu treatment, RAPIVAB approved by the FDA.

BioCryst Receives $20M to develop Ebola Treatment

Durham's Durham’s BioCryst Pharmaceuticals, Inc. received another $2 million to continue development of a possible Ebola virus treatment from the National Institute of Allergy and Infectious Diseases.

BioCryst Awarded $4.1M to Research Ebola Treatment

BioCryst Pharmaceuticals, a small drug developer in Durham, has received a $4.1 million award in federal research funds to develop a potential treatment for the Ebola virus.

BioCryst Adds to Board of Directors

 BioCryst Pharmaceuticals announced that Dr. Fred E. Cohen was elected to the company's Board of Directors.

BioCryst Flu Drug Moves Closer to FDA Filing

BioCryst’sinfluenza treatment Peramivir is a step closer to a filing with the Food and Drug Administration after a meeting with the government agency.

BioCryst Receives Bird Drug Approval in China

Durham's BioCryst's Bird-flue drug has recently been approved for use in China.

BioCryst Starts Clinical Trial

Durham's BioCryst Pharmaceuticals announced Monday that it has started a Phase 1 multi-million-dollar clinical trial to test the safety of its drug that treats hereditary angioedema.

Durham Businesses Win 2012 Triangle Green Business Challenge

The Triangle J Council of Governments recently named award winners for the 2012 Triangle Green Business Challenge. Awards were presented to three Durham businesses; Ninth Street Bakery, Self-Help Credit Union and BioCryst Pharmaceuticals. Twenty-one companies and organizations participated in the challenge to help businesses improve the efficiency and sustainability of their day-to-day operations.

BioCryst, Presidio Call off Merger

Durham-based BioCryst Pharmaceuticals and Presidio Pharmaceuticals terminated their merger agreement, according to an announcement made by the companies on Friday.

Durham Drug Developer BioCryst Pharmaceuticals Set to Buy Presidio Pharmaceuticals

Durham-based drug developer BioCryst Pharmaceuticals is buying San Francisco-based Presidio Pharmaceuticals in an attempt to develop new treatments for hepatitis C.

BioCryst Pharmaceuticals Moves Headquarters

BioCryst Pharmaceuticals, a publicly traded drug development company, is shifting its headquarters to Durham, where it has had offices since 2006.